Consequently, targeted therapeutic approaches in the frequently mutated PI3K–AKT–mTOR pathway in HNSCC cells do not provide an advantage over RT, nor do they bring a supra-additive advantage to KI + IR, as the surrounding tissue is also sensitive to Sapanisertib. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.